Form 4: Ligand Pharmaceuticals Officer Exercises Options and Sells Shares
SEC Form 4
Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, exercised stock options and sold 10,000 shares of common stock on May 9, 2024.
Summary
- On May 9, 2024, Andrew Reardon, the Chief Legal Officer of Ligand Pharmaceuticals, exercised non-qualified stock options to acquire 10,000 shares of common stock at a price of $52.27 per share.
- Simultaneously, Reardon sold 10,000 shares of Ligand Pharmaceuticals' common stock at a weighted-average price of $83.0449, with individual sales prices ranging from $83.00 to $83.27.
- Following these transactions, Reardon directly owns 22,205 shares of Ligand Pharmaceuticals' common stock.
- Reardon also holds non-qualified stock options for 62,944 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard disclosure of insider trading activity.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Stakeholder Impact
- The transaction could have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | Stock option vests and is exercisable as to 12.5% of the underlying shares. |
| 05/09/2024 | Andrew Reardon exercised stock options and sold shares of Ligand Pharmaceuticals. |
| 05/13/2024 | Date of Form 4 filing. |
| 08/01/2032 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.